New data from a systematic literature review highlighted the connection with tumor necrosis factor-α inhibitors and acne, indicating the need for further study.

No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.

Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments and payment per cardiologist.

Data from a meta-analysis show late gadolinium enhancement (LGE) on cardiac MRI scans and elevated fluorodeoxyglucose (FDG) uptake on PET scans are both strong predictors of major adverse cardiac events for cardiac sarcoidosis.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

A new survey found the COVID-19 pandemic changed many Americans view of obesity and caused others to consider new weight-loss methods due to their concerns.

Data also show significant improvements in quality of life and respiratory symptoms in patients with evidence of type 2 inflammation who were treated with dupilumab.

Siperstein highlighted some more major takeaways from her conference presentation, including facts about how to determine which patients are good candidates for microneedling.

The results from the INSPIRE trial show risankizumab met all primary and secondary endpoints in treating adult patients with moderately to severely active ulcerative colitis.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency specifically.

There was very little evidence of an effect growth or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group.

A 14-day randomized clinical trial assessing effects of caffeinated coffee consumption in a population of 100 adult patients, CRAVE offers what could be the most definitive insight yet into the effects of coffee consumption on overall health.

Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference drug.

Proposed biosimilar AVT04 shows comparable efficacy to ustekinumab.

New phase 2b findings support the oral JAK1 inhibitor's capability to improve repigmentation versus placebo.

An analysis of NHANES from 2013 - March 2020 suggest individuals with an indication for statin therapy for primary prevention based on 10-year risk saw low overall use across risk categories and race and ethnicity strata.

“These findings are exciting for us, and our overarching goal is to develop microbial biotherapeutics to treat food allergies," Mustafa Özçam says in an interview with HCPLive.

Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, interview Scott Kahan, MD, MPH who serves on the committee that creates the ADA Standards of Care in Diabetes, to discuss the latest updates in weight management guidelines.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

In this program, we will engage in discussions with a vitiligo patient to explore the impact of the condition on their daily lives, the challenges they face with treatment, and how they manage expectations related to living with vitiligo.

Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.

Clinical remission and clinical response odds, in both induction and maintenance periods, have been consistent over time.

The US FDA has approved an indication for evinacumab for use as an adjunct to other lipid-lowering therapies in children with homozygous familial hypercholesterolemia as young as 5 years old, which makes evinacumab the first ANGPTL3 inhibitor indicted for this patient population.

No single biomarker or multimarker score significantly reached the predefined acceptability thresholds for patients with NASH and clinically significant fibrosis.